DCM
CLVT icon

DME Capital Management’s Clarivate CLVT Stock Holding History

DME Capital Management’s Portfolio CLVT Stock Details CLVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-279,560
Closed -$2.08M – 41
2024
Q1 		$2.08M Buy
+279,560
New +$2.33M 0.1% 35

Other funds holding CLVT

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
ENV
Exor N.V. Amsterdam, Netherlands $5.46B AUM 6.21% 1-Year Est. Return
CCP
Clarkston Capital Partners Rochester, Michigan $1.18B AUM 0.37% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
PGH
Partners Group Holding Baar-Zug, Switzerland $1.47B AUM 8.59% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DME Capital Management's CLVT Position: Q2 2024 in Review

DME Capital Management sold out of Clarivate (CLVT) in Q2 2024, closing a stake of 279,560 shares — an estimated $2.08M sold.

DME Capital Management first reported a position in CLVT in Q1 2024 and held it in 1 quarter. The position peaked at $2.08M in Q1 2024. 207 funds tracked by Wall St. Rank hold CLVT as of Q2 2024.

  • DME Capital Management reported no remaining Clarivate position as of Q2 2024 after selling out during the quarter.
  • DME Capital Management sold 279,560 Clarivate shares in Q2 2024, an estimated $2.08M.
  • DME Capital Management first reported a position in Clarivate in Q1 2024 and held it in 1 quarter.
  • DME Capital Management's Clarivate position peaked at $2.08M in Q1 2024.
  • 207 funds tracked by Wall St. Rank held Clarivate as of Q2 2024.

Based on DME Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.